scispace - formally typeset
Open AccessJournal ArticleDOI

Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension.

TLDR
Given the fatal prognosis of systemic sclerosis–related pulmonary arterial hypertension and the incremental cost per life year of AU$47 989 (US$32 920), combination therapy could be considered cost‐effective in systemic sclerosis‐related pulmonaryarterial hypertension.
Abstract
Background To evaluate the cost‐effectiveness of combination pulmonary arterial hypertension specific therapy in systemic sclerosis–related PAH. Methods and Results Health outcomes and costs were c...

read more

Citations
More filters
Journal ArticleDOI

Systemic sclerosis manifestations and clinical outcomes in Hispanics/Latinos of the American Southwest

TL;DR: Systemic sclerosis phenotype, autoantibodies, complications, outcomes, malignancy rates, and mortality are generally similar between Hispanics and non-Hispanics with systemic sclerosis in the American Southwest, however, age-adjusted comorbid malignancies and mortality rates are significantly increased in both groups.
Journal ArticleDOI

Ligustrazine alleviates pulmonary arterial hypertension in rats by promoting the formation of myocardin transcription complex in the nucleus of PSMCs.

TL;DR: In this paper , the therapeutic effect and target of TMP (tetramethylpyrazine) in the treatment of PAH was studied and it was shown that dramatic changes in myocardin levels can significantly affect the progression of the PAH.
Journal ArticleDOI

A claims‐based, machine‐learning algorithm to identify patients with pulmonary arterial hypertension

TL;DR: In this article , a machine learning algorithm was developed to identify patients at risk for pulmonary arterial hypertension (PAH) earlier in their symptom journey and distinguish them from patients with similar early symptoms not at risk of developing PAH.
References
More filters
Journal ArticleDOI

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

TL;DR: A multicenter, ongoing study of early-diagnosed cases of systemic sclerosis and comparison patients with systemic lupus erythematosus, polymyositis/dermatomyositis, and Raynaud's phenomenon was conducted in order to develop classification criteria for systemic sclerosis.
Journal Article

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

TL;DR: Proposed classification criteria for systemic sclerosis had a 97% sensitivity for definite systemic sclerosis and 98% specificity when applied to the case and comparison patients included in this study.
Journal ArticleDOI

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

Frank H J van den Hoogen, +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Related Papers (5)